- Optimal treatments for newly diagnosed and relapsed patients
- Bispecific and conjugated monoclonal antibodies
- Chemotherapy-free treatments
- Minimal residual disease (MRD) testing in the clinic
- CAR T cell and CAR NK cell therapies
- Future role of bone marrow transplant
- New drugs in development
